Testimony from the bedside: from Coley's toxins to targeted immunotherapy
- PMID: 20609349
- DOI: 10.1016/j.ccr.2010.06.010
Testimony from the bedside: from Coley's toxins to targeted immunotherapy
Abstract
A new clinical study reported in the New England Journal of Medicine unveils the long-awaited outcome of anti-CTLA-4 therapy for melanoma. It provides grounds for continued enthusiasm for cancer immunotherapy, deepens our thoughts on underlying mechanisms, and suggests exciting next steps.
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
